All Posts

iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024, iVEAcare, announced the closure of a $27.5 million Series A financing. The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner. i...

ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. In comparison to other therapeutic options, ravulizumab stands out as a s...

Sanofi is presently engaged in the exploration of Riliprubart (SAR445088), a monoclonal antibody designed to selectively target the serine protease C1s, in pursuit of its potential therapeutic application in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Riliprubart unveils compelling efficacy in CID...

ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. The remarkable reduction in relapse risk observed in the CHAMPION-NMOSD t...

Takeda and Ovid Therapeutics with soticlestat, a first-in-class cholesterol 24-hydroxylase inhibitor, holds promise for transformative therapy marking a milestone in advancing treatment options for individuals with refractory epilepsies associated with Dravet syndrome and Lennox-Gastaut syndrome.  Soticles...

Cenobamate, marketed as XCOPRI in the US and ONTOZRY in the EU, provides various dosage choices to improve treatment adherence and efficacy.  SK Life Science’s cenobamate via its multimodal approach, provides much-needed relief for patients with partial-onset seizures by reducing repetitive neuronal firing...

Athira Pharma presented a poster titled “Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders” at the recently, concluded American Academy of Neurology 2024 Annual Meeting, held in Denver, Colorado. It highlighted preclinical data supporting the development of Athira's pipeline of s...

Semaglutide provides a potential therapeutic avenue for aging-related neurodegenerative diseases, such as Alzheimer's disease through enhanced brain glucose metabolism. The comparable safety data presented by Novo Nordisk strengthens Semaglutide’s profile as a potential candidate in the early Alzheimer’s Diseas...

PRX012, a next-generation subcutaneous antibody, has the potential to eliminate treatment obstacles due to its unique pharmacological properties and improved binding profile compared to conventional amyloid-beta targeting medicines. PRX123, targeting the hallmarks of Alzheimer’s, Aβ plaque, and tau tangles, has...

Donanemab, with improved safety, efficacy, convenient dosing regime, and most importantly its ability to not only prevent but also clear plaques has the potential to redefine the treatment regime for Alzheimer’s patients. With a comparable safety profile, Eli Lilly delivers on even the most basic outcomes essen...